TG Therapeutics Inc
TGTX
查看详细走势图
31.070USD
+0.340+1.11%
收盘 12/24, 16:00（美东）报价延迟15分钟
4.82B总市值
10.15市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.11%
5天
+3.81%
1月
-5.79%
6月
-16.61%
今年开始到现在
+3.22%
1年
-3.39%
查看详细走势图
TradingKey TG Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
TG Therapeutics Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名80/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价44.29。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
TG Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
买入
评级
44.286
目标均价
+43.64%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
TG Therapeutics Inc亮点
亮点风险
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
业绩高增长
公司营业收入稳步增长，连续3年增长11713.43%
估值合理
公司最新PE估值10.15，处于3年历史合理位
机构减仓
最新机构持股101.46M股，环比减少14.52%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值979.27K
活跃度增加
近期活跃度增加，过去20天平均换手率-0.19
TG Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
TG Therapeutics Inc简介
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
公司代码TGTX
公司TG Therapeutics Inc
CEOWeiss (Michael S)
网址https://www.tgtherapeutics.com/
常见问题
TG Therapeutics Inc(TGTX)的当前股价是多少？
TG Therapeutics Inc(TGTX)的当前股价是 31.070。
TG Therapeutics Inc的股票代码是什么？
TG Therapeutics Inc的股票代码是TGTX。
TG Therapeutics Inc股票的52周最高点是多少？
TG Therapeutics Inc股票的52周最高点是46.480。
TG Therapeutics Inc股票的52周最低点是多少？
TG Therapeutics Inc股票的52周最低点是25.280。
TG Therapeutics Inc的市值是多少？
TG Therapeutics Inc的市值是4.82B。
TG Therapeutics Inc的净利润是多少？
TG Therapeutics Inc的净利润为23.38M。
现在TG Therapeutics Inc(TGTX)的股票是买入、持有还是卖出？
根据分析师评级，TG Therapeutics Inc(TGTX)的总体评级为买入，目标价格为44.286。
TG Therapeutics Inc(TGTX)股票的每股收益（EPS TTM）是多少
TG Therapeutics Inc(TGTX)股票的每股收益（EPS TTM）是3.060。
相关品种
